insights_auto
Why is 6160 up 4,36%?
Dive Deeperchevron_right
6160:HKG
BeOne Medicines AG
225,00 HK$
arrow_upward
+4,36%(+9,40) 1D
16 հոկ, 16:08:14 GMT+8 · HKD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 6160...
Open
224,80 HK$
High
230,20 HK$
Low
221,80 HK$
Mkt. cap
355,76 մլրդ
Avg. vol.
2,93 մլն
Volume
4,41 մլն
P/E ratio
65,67
52-wk high
235,60 HK$
52-wk low
153,00 HK$
EPS
3,43 HK$
Shares outstanding
1,43 մլրդ
No. of employees
12 հզր
Open
224,80 HK$
High
230,20 HK$
Low
221,80 HK$
Mkt. cap
355,76 մլրդ
Avg. vol.
2,93 մլն
Volume
4,41 մլն
P/E ratio
65,67
52-wk high
235,60 HK$
52-wk low
153,00 HK$
EPS
3,43 HK$
Shares outstanding
1,43 մլրդ
No. of employees
12 հզր
News stories
From web sources and news partners
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12 հզր
Founded28 հոկ, 2010 թ.
Headquarters-
Sector-
Websitebeonemedicines.com